Ingelheim, Germany, 01 November 2011: Today, the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has issued a Final Appraisal Determination (FAD) 1 recommending the novel oral anticoagulant, Pradaxa® (dabigatran etexilate), as a treatment option without any restrictions within its licensed indication for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation (AF) with one or more risk factors . The FAD will form the guidance to the National Health Service (NHS) in England and Wales, which is expected to be published in December.
NICE issues Final Appraisal Determination (FAD) with unrestricted recommendation for Pradaxa® (dabigatran etexilate) for patients with non-valvular atrial fibrillation
The FAD states that Pradaxa® “is a cost-effective use of National Health Service (NHS) resources when used within its licensed indication.” - For NON-US, UK & Canada Media Only
Nov 2nd, 2011
